[Treatment of unfit acute myeloid leukemia].

Treatment strategies for unfit patients with acute myeloid leukemia (AML) are undergoing fundamental changes. Recent advances in molecularly targeted therapies have led to the development of safe and effective regimens, providing new treatment options. Every day, important findings are emerging that are dramatically changing the treatment paradigm for patients with unfit AML. New risk classifications based on clinical data from unfit cases are being developed in response to identification of prognostic factors determining response to the new standard therapy, venetoclax plus azacitidine, as well as to newer regimens. This article reviews validated clinical trial data for unfit AML and discusses the current best treatment options and future challenges.